Inflammation and long-term mortality in acute congestive heart failure - 17/08/11
, Kirsten Laule-Kilian, BSc, Andreas Christ, MD, Hans Peter Brunner–La Rocca, MD, André P. Perruchoud, MDRésumé |
Background |
Systemic inflammation has long been recognized as a precipitator of acute congestive heart failure (CHF). The impact of inflammation on prognosis in acute CHF, however, is unknown.
Methods |
This study evaluated the prognostic role of inflammation among 214 consecutive patients presenting with acute CHF to the emergency department. Patients were stratified according to C-reactive protein (CRP) levels determined on admission. The primary end point was all-cause mortality during 24-month follow-up.
Results |
The median CRP level was 13.0 mg/L, with an intertertile range of 6.0 to 25.0 mg/L. Initial and long-term outcomes were significantly different to the detriment of patients with higher CRP levels. Patients in the highest CRP tertile significantly more often required admission to the intensive care unit (33% vs 14% in patients in the first tertile, P = .028) and died inhospital (15% vs 2% in patients in the first tertile, P = .027). Cumulative 24-month mortality rates were 33.5% in the first, 42.4% in the second, and 53.6% in the third tertile (P = .0265 by log-rank test). After multivariate adjustment, CRP remained an independent predictor of death (hazard ratio 1.4, 95% CI 1.1-1.8 for each step up in tertile, P = .044).
Conclusions |
Inflammation is a significant and independent predictor of long-term mortality in patients with acute CHF.
Le texte complet de cet article est disponible en PDF.Plan
| This study was supported by research grants from the Swiss National Science Foundation, the Swiss Heart Foundation, and the Novartis Foundation (Dr Mueller). |
Vol 151 - N° 4
P. 845-850 - avril 2006 Retour au numéro
Article précédent
- Rapid titration of carvedilol in patients with congestive heart failure: A randomized trial of automated telemedicine versus frequent outpatient clinic visits
- Jeffrey Spaeder, Samer S. Najjar, Gary Gerstenblith, Gail Hefter, Linda Kern, James G. Palmer, Sheldon H. Gottlieb, Edward K. Kasper
- A randomized, placebo-controlled, double-blind, crossover study to evaluate the efficacy of oral sildenafil therapy in severe pulmonary artery hypertension
- Tarvinder P. Singh, Manojkumar Rohit, Anil Grover, Samir Malhotra, Rajesh Vijayvergiya
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?